TB Online is no longer maintained. This is an archive of the site. For news on TB please go to:
https://globaltbcab.org/SQ109 to be evaluated for efficacy on multi-drug resistant patients
Sequella
July 27, 2012, 4:05 a.m.
Maxwell Biotech Venture Fund’s portfolio company, Infectex, receives Russian regulator’s approval to conduct pivotal clinical trial for Sequella’s antibiotic, SQ109, for tuberculosis.
Download the full press release from here.
Sequella
http://www.sequella.com/